Sionna Therapeutics, Inc. (NASDAQ:SION)
| Market Cap | 212.21M-83.5% |
| Revenue (ttm) | 0 |
| Net Income | -97.38M-28.4% |
| EPS | -2.18-26.5% |
| Shares Out | 45.15M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 18,296 |
| Open | 4.78 |
| Previous Close | 4.82 |
| Day's Range | 4.65 - 4.78 |
| 52-Week Range | 4.01 - 54.97 |
| Beta | 1.32 |
| Analysts | Hold |
| Price Target | 27.40(+482.98%) |
| Earnings Date | Nov 4, 2026 |
Insiders filed in the last 90 days, but none of those trades qualified for scoring — round-trip buys and filings whose price is far off the market are excluded.
About SION
Sionna Therapeutics, Inc., a clinical-stage biopharmaceutical company, researches and develops medicines for the treatment of cystic fibrosis (CF). It develops galicaftor (SION-2222), a transmembrane domain 1 (TMD1)-directed cystic fibrosis transmembrane conductance regulator (CFTR) that has completed Phase 2 trial; navocaftor (SION-3067), a potentiator that has completed Phase 2 trial; SION-109, an intracellular loop 4 directed CFTR corrector that has completed Phase 1 trial; SION-2851, a TMD1-directed CFTR corrector that has completed Phase 1 trial; SION-451, which is nucleotide-binding domain 1 stabilizer in Phase 1 trial; and SION-719, which is nucleotide-binding domain 1 stabilizer in Phase 2a proof-of-concept trial. The company was formerly known as Sling Therapeutics, Inc. and changed its name to Sionna Therapeutics, Inc. in July 2021. Sionna Therapeutics, Inc. was incorporated in 2019 and is headquartered in Waltham, Massachusetts.
What Are Insiders Doing?
View the trades behind this meter — each links to its SEC Form 4 →
Open-market Form 4 purchases (code P) vs sales (code S) on file for this company. Grants, option exercises and tax withholdings are excluded. Informational only.
$SION stock is featured in our Insider Score Rankings, and Insider Trades datasets.
→ All Stock ListsRecently reported changes in SION holdings by institutional investors
Latest 0 13F filings · Source: SEC EDGAR
View all institutional owners →Insider Trading
Quarterly net insider trading by SION's directors and management
Source: SEC EDGAR (Form 4)
Corporate Lobbying
SION Estimated quarterly lobbying spending
Source: U.S. Senate LDA
U.S. Patents
New SION patent grants
Source: USPTO Open Data Portal
Government Contracts
Estimated quarterly amount awarded to SION from public contracts
Source: USAspending.gov
Top ETF Holders
ETFs with the largest estimated holdings in SION
| ETF | Est. Holding Size |
|---|---|
| VTIVanguard Morningstar Total Stock Market ETF | $5.64M |
| VFMOVanguard U.S. Momentum Factor ETF | $2.42M |
| IWMiShares Russell 2000 ETF | $2.33M |
| VXFVanguard Extended Market ETF | $1.01M |
| IBBiShares Biotechnology ETF | $968.82K |
| IWOiShares Russell 2000 Growth ETF | $842.13K |
Estimated from each fund’s disclosed top holdings × AUM
SION Insider Score
Our composite score: insider buying, sector, volume, tone & dilution
Bull Case vs Bear Case
AI-generated from SION’s recent data — informational, not investment advice
Insider Score
Our 0–100 Insider Score and the signals behind it.
The live Insider Score and its full factor breakdown are included with Insider Access.
Unlock Insider Score